CYP4F2-catalyzed metabolism of arachidonic acid promotes stromal cell-mediated immunosuppression in non-small cell lung cancer

Xuehan Chen,Yanzhuo Liu,Yang Wang,Chenlong Wang,Xuewei Chen,Yu Xiong,Lilong Liu,Xi Yuan,Honglin Tang,Chong Shu,Jing Zhang,Honglei Chen,Jing Yang,Austin M. Guo
DOI: https://doi.org/10.1158/0008-5472.can-21-4029
IF: 11.2
2022-08-26
Cancer Research
Abstract:Fatty acid synthesis facilitates tumor cell immune escape and immunotherapy resistance. Cytochrome P450 (CYP) 4A and 4F, the major ω-hydroxylases that convert arachidonic acid (AA) into 20-hydroxyeicosatetraenoic acid (20-HETE), are implicated in inflammation and cancer. However, the role of CYP4 ω-hydroxylases in immune evasion remains unclear. Here, we determined that 20-HETE derived from the CYP4F2 isoenzyme governs immune evasion in non-small cell lung cancer (NSCLC) in a CD8+ T cell-dependent manner. Mechanistically, CYP4F2 induced expression of immune checkpoint PD-L1 and production of proangiogenic factors IL-6 and TGF-β in cancer-associated fibroblasts (CAF) via the 20-HETE-GPR75-STAT3-c-Jun axis. Tumors with high CYP4F2 expression were more resistant to anti-PD-1 treatment, while inhibition of CYP4F2 enhanced the efficacy of anti-PD-1 therapy in human NSCLC organoids and mouse models. Collectively, these data delineate that CYP4F2-dependent AA metabolism controls CAF-mediated immune evasion. CYP4F2 inhibition combined with PD-1 antibody represents a promising therapeutic approach for immunotherapy-resistant lung cancer.
oncology
What problem does this paper attempt to address?